This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CVS Q1 Earnings & Revenues Beat, '25 EPS View Raised, Stock Up
by Zacks Equity Research
CVS Health delivers earnings and revenue beat in the first quarter of 2025.
Labcorp Q1 Earnings Surpass Estimates, Revenues Miss, Stock Gains
by Zacks Equity Research
LH delivers better-than-expected earnings in the first quarter of 2025.
Integer Holdings Q1 Earnings & Revenues Beat Estimates, Margins Expand
by Zacks Equity Research
ITGR tops first-quarter estimates with strong sales and EPS growth. Margins expand, driven by new products, acquisitions, and operational efficiency.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Integer (ITGR) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 3.15% and 1.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
What Analyst Projections for Key Metrics Reveal About Integer (ITGR) Q1 Earnings
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Integer (ITGR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Why Integer (ITGR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Integer (ITGR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Integer (ITGR) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Strength Seen in Artivion (AORT): Can Its 7.9% Jump Turn into More Strength?
by Zacks Equity Research
Artivion (AORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio
by Zacks Equity Research
ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.
Here's Why Integer (ITGR) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Integer (ITGR) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Integer (ITGR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Integer (ITGR) Soars 3.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Integer (ITGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Integer (ITGR) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can ITGR Stock's Growth Drivers Offset Rising Risks in 2025?
by Zacks Equity Research
Integer Holdings projects 8-10% sales growth in 2025, driven by acquisitions and high-demand medical technologies. But, can it overcome tariff and margin pressures?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Company News for Feb 24, 2025
by Zacks Equity Research
Companies in The News Are: ABR,ED,MELI,ITGR
ITGR Stock Declines Following Q4 Earnings Miss, Gross Margin Contract
by Zacks Equity Research
Integer Holdings' fourth-quarter results reflect robust sales from the majority of the product lines, along with continued product adoption.
Integer (ITGR) Misses Q4 Earnings Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of -2.05% and 0.75%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
What to Expect From These 3 MedTech Stocks This Earnings Season?
by Indrajit Bandyopadhyay
Here is a sneak peek into how three MedTech stocks, GKOS, ITGR and AMN, are expected to fare in their quarterly results, slated to be released tomorrow.
Insights Into Integer (ITGR) Q4: Wall Street Projections for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Integer (ITGR) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.